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Background: In patients with stable coronary artery disease (CAD), decisions regarding revascularisation are
primarily driven by the severity and extent of coronary luminal stenoses as determined by invasive coronary
angiography. More recently, revascularisation decisions based on invasive fractional flow reserve (FFR) have shown
improved event free survival. Cardiovascular magnetic resonance (CMR) perfusion imaging has been shown to be
non-inferior to nuclear perfusion imaging in a multi-centre setting and superior in a single centre trial. In addition, it
is similar to invasively determined FFR and therefore has the potential to become the non-invasive test of choice to
determine need for revascularisation.
Trial design: The MR-INFORM study is a prospective, multi-centre, randomised controlled non-inferiority, outcome
trial. The objective is to compare the efficacy of two investigative strategies for the management of patients with
suspected CAD. Patients presenting with stable angina are randomised into two groups: 1) The FFR-INFORMED
group has subsequent management decisions guided by coronary angiography and fractional flow reserve
measurements. 2) The MR-INFORMED group has decisions guided by stress perfusion CMR. The primary end-point
will be the occurrence of major adverse cardiac events (death, myocardial infarction and repeat revascularisation) at
one year. Clinical trials.gov identifier NCT01236807.
Conclusion: MR INFORM will assess whether an initial strategy of CMR perfusion is non-inferior to invasive
angiography supplemented by FFR measurements to guide the management of patients with stable coronary
artery disease. Non-inferiority of CMR perfusion imaging to the current invasive reference standard (FFR) would
establish CMR perfusion imaging as an attractive non-invasive alternative to current diagnostic pathways.
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Table 1 Detailed definition of end-points
End Point Definition
Death All cause mortality
Myocardial
Infarction
Spontaneous Elevation of CK or Troponin above
baseline with symptoms of ischaemia,
ECG changes or imaging evidence
of loss of myocardium [22]
Peri-procedural CKMB >3x ULN - upper limit of normal
(post PCI 12-24 hrs) CKMB >5x ULN
(post CABG 24-72 hours) plus new Q
waves or LBBB, new native vessel or
graft occlusion, imaging evidence of
loss of viable myocardium [22]
Repeat
revascularisation
Repeat PCI or CABG of the target lesion
performed for restenosis or other
complication of the target lesion (from
5 mm proximal to 5 mm distal to the
stent) [23]
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Over the last few years, there have been a number of
landmark trials questioning previously accepted manage-
ment strategies for patients with stable coronary artery
disease. The COURAGE [1] trial has shown no benefit of
routine revascularisation both in terms of prognosis and
long term symptom relief in patients with stable angina.
However, subgroup analysis of the COURAGE data [2],
suggests that the prognosis of patients receiving optimal
medical therapy (OMT) alone or percutaneous coronary
intervention (PCI) and OMT is correlated to their is-
chaemic burden and the amount of ischaemia reduction
achieved by therapy, as assessed by single-photon emis-
sion computed tomography (SPECT). The assessment of
prognosis, however, was exploratory, and not associated
with outcome when adjusted for treatment.
There is evidence that the presence of stress-induced
myocardial perfusion defects identified by non-invasive
imaging tests such as SPECT have prognostic significance
[3]. An observational study of 10 627 patients with stable
angina and evidence of ischaemia as measured by SPECT
described a survival advantage for revascularisation
(of which 52% was PCI) over medical therapy in patients
with ischaemia of more than 10% of the myocardium [4].
An alternative approach is the use of invasive fractional
flow reserve (FFR) measurements to assess the functional
significance of coronary stenoses. The FAME [5] and
DEFER [6] trials have demonstrated that patients in whom
angioplasty is only performed on FFR positive stenoses
have an improved outcome compared to those patients in
whom the revascularisation decision is based on a visual
estimate of angiographic severity alone. The 2-year follow-
up of the FAME patients showed a significant reduction
in major cardiac events (MACE) in patients guided by
FFR. Thus, there is accumulating evidence dictating a shift
away from a purely anatomical assessment for coronary
artery disease to a functional assessment. These data are
of specific importance as most studies so far have deter-
mined diagnostic accuracy, whereas FAME and DEFER are
among the few studies, where different diagnostic strategies
were used to guide further management and thus improve
outcome.
Cardiovascular magnetic resonance (CMR) perfusion is a
well-established, non-invasive test with excellent accuracy
for the detection of coronary artery stenoses [7] as well as
abnormal FFR [8,9]. Multicentre data has demonstrated
non-inferiority of CMR myocardial perfusion imaging in
comparison to SPECT for the assessment of myocardial is-
chaemia [10]. In a recent single centre study of 750
patients the superiority of CMR perfusion in comparison
to SPECT was shown mainly due to improved sensitivity
(86.1% vs 65.5%) [11]. In addition, patients with a negative
perfusion scan have a low likelihood (<1%) of a major car-
diac event over the following two years [12-14]. Thus,CMR perfusion seems well suited to guide the manage-
ment of patients with stable coronary artery disease similar
to invasive FFR measurements [15].
Although treatment decisions are increasingly being
based on the combination of symptoms and objective
proof of ischaemia, there is insufficient evidence on the
best management strategy for patients with stable angina
[16] and comparative effectiveness. The aim of the MR-
INFORM study, therefore, is to establish whether guid-
ing the management of patients with a moderate to high
risk of coronary artery disease by CMR perfusion is non-
inferior to guiding the management of these patients by
invasive angiography and FFR.
Methods
Hypothesis
The principal hypothesis is that selecting patients with
stable angina for revascularisation and optimal medical
therapy (OMT) or OMT alone based on CMR myocardial
perfusion is non-inferior to selecting patients based on
routine coronary angiography and fractional flow reserve
(FFR) in terms of subsequent major adverse cardiac events.
Endpoints
Primary endpoint
The primary endpoint is the occurrence of a Major Ad-
verse Cardiac Event (MACE) at one year. This is a com-
posite end-point of death, myocardial infarction, and
repeat target vessel revascularisation. See Table 1 for
detailed definitions of endpoints.
Secondary endpoints
 Symptoms (angina score, NYHA class) within 1 year.
 Death, myocardial infarction and repeat
revascularisation as individual components of
MACE.
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for vascularisation.
 Occurrence of new myocardial scar tissue.
 Ischaemia reduction in the FFR vs CMR group after
therapy.
Study conduct and randomisation
MR-INFORM is a multi-centre, randomised controlled,
non-inferiority trial. It is actively recruiting within the UK,
Germany and Portugal. The study is performed in accord-
ance with the principles of the Declaration of Helsinki;
with all patients providing informed written consent prior
to testing. The study protocol and other relevant docu-
mentation have been approved by the South London Ethics
Committee (UK) and the relevant national ethics commit-
tees as well as registered on ClinicalTrials.gov identifier:
NCT01236807: (http://clinicaltrials.gov/ct2/show/NCT012
36807?term=MR+ INFORM&rank=1). Suitable patients
are identified in the outpatient clinics and from the angiog-
raphy and CMR waiting lists of the recruiting centres. IfFigure 1 Study Flow diagram outlining the study design. *CXA=Coronthey meet the inclusion criteria and none of the exclusion
criteria and provide written informed consent, they are en-
rolled into the study.
Patients are electronically randomised prior to the
baseline CMR scan via a web-based randomisation ser-
vice into randomly varying block sizes of 2 and 4, strati-
fied by study site and gender with an allocation ratio 1:1
to MR-INFORMED or FFR- INFORMED (Figure 1).Patient population
Patients recruited into the study have typical symptoms of
angina (Canadian Class Symptoms CCS 2-3), and either a
positive exercise/bicycle test or more than two cardiovas-
cular risk factors. Exclusion criteria include contra-
indications to CMR imaging or to adenosine, poor renal
function (eGFR<30), LVEF <30%, PCI within the last
6 months, and previous CABG. A prior myocardial infarc-
tion is not an exclusion criterion. The complete inclusion
and exclusion criteria are listed in Table 2.ary Angiography.
Table 2 Inclusion and Exclusion criteria
Inclusion criteria Exclusion criteria
CCS Class 2 and 3AND EITHER: 2 or more of the following risk factors (diabetes,
hypertension, smoking, family history, hypercholesterolaemia) OR Positive
Exercise treadmill/bicycle test
Contra-indications to CMR
Contra-indications to adenosine (AV-block2 or 3, symptomatic
bradycardia, COPD with evidence of bronchospasm or asthma)
Cardiac arrhythmias which may compromise image quality, atrial
fibrillation or frequent ectopic beats > 20 bpm)
Age > 18 yrs Known Left ventricular ejection fraction of less than 30%
Willing to undergo all study procedures Persistent CCS class 4 angina
NYHA class 3 and 4
Previous coronary artery bypass grafts
PCI within the previous 6 months
Poor renal function (GFR< 30 ml/min) and /or allergy to contrast
media
Inability to lie supine for 60 mins
Unstable medically
Participating in any other clinical trial
Pregnancy / breast feeding
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and further management will depend on whether they
have been randomised to the MR-INFORMED or the
FFR-INFORMED arm of the trial. In addition, all
patients receive optimal medical therapy.
FFR INFORMED group
Within the FFR-INFORMED group, the baseline CMR scan
is blinded. This scan is not used to guide further manage-
ment but will provide valuable additional scientific data that
will be used in analyses specific to the substudies (described
below). All patients in this group are examined with inva-
sive angiography, FFR is performed in all arteries > 2.5 mm
with a diameter stenosis > 40%. FFR is attempted in all ar-
teries up to a 99% stenosis, as long as patency is not com-
promised. Although this strategy differs from clinical
practice, which tends to focus more on intermediate
lesions, evidence from the FAME trial suggests that even in
severe and mild stenosis the visual estimate can be inaccur-
ate [17]. The cut-off of 40% was used to ensure that all
stenoses in the intermediate group i.e 50 -70% were interro-
gated with the pressure wire. The results of invasiveTable 3 Risk factor goals
Risk Factor Goals
Blood Pressure BP 130/80 mmHg
Diabetes Mellitus Fasting or pre-prandial glucose of 4-6,
or a HbA1C< 6.5%
Lipids Total cholesterol less than 4 mmol/l
or an LDL < 2.0 mmol/l
Smoking Smoking cessation
Weight BMI < 25angiography and the FFR are used to guide further treat-
ment. Any narrowing with an FFR of > 0.8 is regarded as
not haemodynamically significant, whereas a narrowing
with an FFR of ≤0.8 or a total occlusion is regarded as sig-
nificant and revascularisation is indicated. The decision on
the mode of revascularisation is left to the treating Cardi-
ologist and depends on local practice. In the case of repeat
revascularisation, when symptoms are ongoing, revasculari-
sation will be guided according to either the FFR or CMR
results depending on the group randomised.MR- INFORMED group
Within the MR-INFORMED group, further management
is dictated by the results of the baseline CMR scan. A
visual assessment of the significance of ischaemia and
the territories involved is made (see investigation report-
ing below). Patients with significant perfusion defects
are referred for angiography and revascularisation is
guided by the ischaemic territories identified on the
CMR scan in combination with the results of the angio-
gram. FFR should not be done in this group.Baseline and follow-up visits
All patients undergo a thorough cardiovascular risk assess-
ment at baseline with measurement of blood pressure,
glucose levels, body mass index, including measurement
of waist circumference, full lipid profile, the completion of
a health questionnaire (EQ-5D) and a 12 lead ECG. Symp-
tomatic status is recorded by CCS and NYHA class. Med-
ical therapy is optimised in all patients and the risk factor
assessments are repeated at 6 and 12 months to assess the
impact of medical therapy.
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done in a subgroup of patients to assess for residual is-
chaemia, new scar formation and changes in left ven-
tricular function and size after the initial therapy
recommended after the baseline investigations. The re-
sult of this CMR scan will remain blinded.Optimal medical therapy
At baseline, 6 months and 12 months recommendations
for therapy are made to the primary care physician in line
with guidelines published by the Joint British Societies
[18]. See Table 3 for the treatment targets.
The goal of anti-hypertensive therapy is to achieve a
blood pressure of less than 130/80 mmHg. The choice of
anti-hypertensive therapy will be left to the treating phys-
ician.The aim of anti-lipid therapy is to achieve levels of
LDL <2 mmol/l and total cholesterol < 4 mmol/l. In the
first instance, statin therapy will be initiated and then
increased with the addition of a second agent if necessary.
For patients with a BMI of > 25 kg/m2, the primary health
care physicians are asked to refer the patient for dietary
advice. Similarly, smokers are referred to the smoking ces-
sation clinic. Recommendations for referral and for the
continuation of therapy are made to the primary health
care physician.
In patients without diabetes, who have a raised ran-
dom glucose, the primary health care physician is asked
to repeat a fasting glucose to assess for sustained hyper-
glycaemia, in which case the appropriate dietary advice
and/or diabetic treatment should be instituted. In the
case of diabetics with a raised blood sugar, the primary
health care physician is asked to measure HbA1c and to
ensure that the patients’ subsequent therapy is tailored
to achieve a HbA1c of less than 6.5 mg/dl. All patientsFigure 2 MR-INFORM cardiac magnetic resonance protocol. After indiv
given according to the protocol. First pass stress perfusion imaging is done
agent bolus through the myocardium. Short axis (SA) cine images are acqu
second bolus of 0.75 mmol/kg contrast agent. 10 minutes after an addition
dose of contrast agent to 0.2 mmol/kg is given. A modified Look-Locker in
imaging in short axis and long axis views. During the wait time after the la
chamber and the 2 chamber views are obtained.should be prescribed aspirin (clopidogrel if aspirin sensi-
tive), statin therapy and an ACE Inhibitor [19].
Investigations
CMR scanning
CMR imaging will be performed on 1.5 T scanners (vari-
ous vendors); total scan duration will be approximately
one hour. All images will be acquired using phased array
surface coils during mild expiration and electrocardio-
graphic triggering. Cine images will be acquired in the
4-, 3-, 2-chamber and contiguous short axis views using
a steady state free precession (SSFP) sequence (Figure 2).
For perfusion, a basal, midventricular, and apical short
axis slice will be acquired during the first pass of
0.075 ml/kg of a 1-molar gadolinium based contrast
agent injected with a power injector at a flow rate of
4mls/s. The exact details of the sequence will vary be-
tween different scanners used but will fulfill certain basic
criteria, including high spatial resolution(< 3 mm x
3 mm), acquisition duration < 180 ms per slice, 90° satur-
ation pre-pulse, fixed pre-pulse delay and dual bolus con-
trast injection allowing semi-quantitative and fully
quantitative analysis [20]. Hyperaemia will be achieved by
infusion of adenosine at 140mcg/kg/min for 3-4 minutes.
If there is neither a heart rate increase > 10 bpm nor a sys-
tolic blood pressure drop > 10 mmHg from baseline nor
symptoms the adenosine dose will be increased to 170
mcg/kg/min after 2 minutes and to a maximum dose of
210 mcg/kg/min [21]. All patients will be asked to avoid
caffeine, but to continue with their normal medication for
12 hours prior to the scan. For the perfusion measure-
ments, contrast agent will be injected at the third minute
of adequate adenosine stress using a dual bolus method. A
dose of 0.075 mmol/kg of a 1-molar gadolinium-chelate
(Gadobutrol, GadovistW, Bayer, Germany) will be injectedidual patient planning using survey scans, intravenous adenosine is
during stress visualizing the first passage of a 0.75 mmol/kg contrast
ired. Rest perfusion images are acquired during an injection of a
al injection of 0.05 mmol/kg of contrast agent to increase the total
version time scout is performed prior to late gadolinium enhancement
st contrast agent injection long axis images in the 4 chamber, 3
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diluted contrast agent dose for a prebolus both flushed
with 25 ml of saline. Rest perfusion imaging will be per-
formed 10 min after stress perfusion to allow for clearance
of most of the contrast agent.
Late enhancement imaging will then be carried out
using an inversion recovery turbo gradient echo sequence.
Coronary angiography and pressure wire measurements
At angiography, any arteries with a diameter of > 2.5 mm
and a diameter stenosis between 40–99% will be assessed
with FFR. A 0.014 guidewire (Radiwire, St. Jude Medical,
St. Paul, MN, USA or Volcano, Volcano Corporation, San
Diego, CA) will be introduced, calibrated and advanced
into the coronary artery distal to the stenosis. An intraven-
ous adenosine infusion (140 mcg/kg/min) will be used to
induce maximal hyperaemia. FFR is calculated as the ratio
of the mean distal coronary pressure measured by the
guidewire to mean aortic pressure measured by the guid-
ing catheter. Revascularisation will be recommended in
the FFR group if FFR is < 0.80. In the case of a chronic
total occlusion, FFR is regarded as positive and a default
value of 0.5 is assigned to the chronically occluded vessel.
In the case of triple vessel disease, an attempt should be
made to do FFR in all three arteries.
Investigation reporting
CMR analysis
The CMR analysis for the MR-INFORMED group will
be done by the local supervising CMR physicianas per
normal clinical practice.
The following data will be collected:
1) Image quality (assessed on a grade of 1 to 4 – poor
to excellent).
2) Presence of scar tissue and transmurality (1 = 1-25%;
2 = 25-50%; 3 = 51-75%; 4 = > 75%) based on the
AHA/ACC 17 segment model.
3) Perfusion analysis at stress and rest scored as
significant, insignificant or no defect based on the
AHA/ACC 16 segment model (see below).
4) Evidence of regional wall motion abnormalities
(1 = akinetic; 2 = hypokinetic; 3 = dyskinetic).
5) Quantitative analysis including end-diastolic and
end-systolic volumes and ejection fraction.
The baseline CMR scan in the FFR-INFORMED group
will remain blinded.
Perfusion analysis
The CMR perfusion images will be interpreted visually
and angiography recommended if the perfusion defect is
classified as significant according to the presence ofischaemia in 2 segments of a 32 segment model (see
below) i.e:
 > 60 degrees in either the basal or the
midventricular slices or
 > 90 degrees in the apical slice or
 any transmural defect or
 two adjacent slices.
In the case of patients who have unexpected scar tis-
sue evident on CMR, angiography would be recom-
mended for all patients who have evidence of scar and
peri-infarct ischaemia. When only scar is present, the
management will be decided after an assessment of the
transmurality of scar. In patients with transmural scar
(> 75%), and no additional ischaemia, angiography would
not be recommended. In patients with partial transmur-
ality (< 75%), and no ischaemia, the need for angiography
will be decided by the treating physician after an assess-
ment of the patient’s symptoms and risk. It is recom-
mended, however, that the subsequent revascularisation
strategy be guided by the areas of ischaemia alone.
The rationale for the threshold at which ischaemia
is deemed to be significant is based on data from
Hachamovitch et al. [4] who demonstrated that in patients
with 10 – 12.5% ischaemic myocardium on SPECT, mortal-
ity is significantly higher if they are not revascularised in
comparison to a revascularised group. The opposite is true
in patients with less than 10% ischaemic myocardium.
With the high spatial resolution of CMR perfusion
(< 3 mm x 3 mm) it is possible to distinguish endocar-
dial, non-transmural, perfusion defects from transmural
(> 75% wall thickness) perfusion defects. Thus, the
myocardium can be divided into the 16 AHA/ACC
segments with a subdivision into an endocardial and an
epicardial half resulting in a total of 32 segments. Each of
these segments represents approximately 3% of the myo-
cardium, two positive segments represent approximately
6%. Since there is no data available providing a direct com-
parison between the ischaemic burden in SPECTand CMR
perfusion this level is used as a conservative threshold to
refer patients to invasive angiography.
The criteria for interpretation of CMR scans, especially
the differentiation between normal myocardium, non-
transmural defects, and transmural defects, will be dis-
cussed in detail with each site during the initiation visit
using a set of example cases. In addition, CMR images
will be periodically reviewed by the global coordinating
investigator and selected coordinating investigators from
participating countries who – in case of inconsistencies
or differences in assessment – will contact the sites and
consider specific training activities. Each site can invite a
second opinion from the global coordinating investiga-
tor or a coordinating investigator from a participating
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clear cases.
Invasive angiography
The results of the coronary angiogram will be assessed
by the operator at the time of the angiogram. The fol-
lowing data will be collected:
 Coronary artery dominance
 Location and presence of stenosis by visual estimate
 Vessel diameter
 FFR measurement in all arteries > 2.5 mm with a
diameter stenosis greater than 40% but not
chronically occludedon visual assessment.
Revascularisation
Revascularisation by either (PCI) or coronary artery bypass
grafting (CABG) will be guided by the ischaemic territories
identified by either FFR or CMR perfusion, depending on
the randomisation group. For example, if the CMR perfu-
sion scan demonstrates a perfusion defect in the left anter-
ior descending (LAD) territory and angiographically a
narrowing is identified in the LAD and right coronary ar-
tery (RCA), only the LAD artery will be revascularised.
In visual triple vessel disease, the FFR or CMR results
will be used to guide the decision towards CABG or PCI.
If there is more than one artery that needs to be revas-
cularised, the PCI procedure can be staged. If this
occurs, follow-up will begin after the first procedure,
and the endpoints will include both procedures.
Post-interventional FFR is useful but not mandated in
order to keep the procedure as simple as possible.
The specific revascularisation technique, i.e. type of stents
used, staging of the procedure, PCI or CABG etc. will be
decided by the treating interventionalist and dictated by
local guidelines. This is to reflect “real –world” practice and
to acknowledge that practice varies between centres and
countries. Similarly, the cardiac surgeons will decide on the
type of surgical revascularisation that they will undertake.
In the case of patients who demonstrate scar and is-
chaemia on CMR perfusion subsequent revascularisation
will be guided by areas of ischaemia alone rather than
on the basis of scar.
Substudy analyses
A number of substudies will be performed based on the
data acquired during the main study. These will not
interfere with the aims and the conduct of the main trial
but will provide valuable additional data. The major sub-
studies are:
1. Determination of an ischaemic threshold for
revascularisation with semi-quantitative and fully
quantitative perfusion analysis.2. Correlation between the results of FFR and CMR
perfusion.
3. Ischaemia reduction in the MR-INFORMED vs the
FFR-INFORMED group
4. The effect of new scar formation on outcome.
5. The cost-effectiveness of an MR-INFORMED vs a
FFR-INFORMED revascularisation strategy.
Data collection and monitoring
Patient demographic details, medical history and infor-
mation on current medication use will be collected. A
12 lead ECG will be performed at baseline and at
12 months. Blood tests will include a measurement of
total cholesterol and full lipid profile, a random glucose
measurement, and renal function (eGFR). These tests
will be repeated at 6 and 12 months. A full blood count
will also be measured at baseline. Blood pressure, waist
circumference measurement, and Body Mass Index will
be determined at baseline, 6 and 12 months.
At the time of revascularisation (PCI or CABG), base-
line troponin will be measured. This will then be
repeated 6 hours post PCI or 12 hours post CABG. If
the troponin is raised, then a CKMB will be done at 12-
24 hours post PCI or 36-72 hours post CABG. The defin-
ition of myocardial infarction is based on CKMB. See
Table 1 for detailed definitions of end-points.
All study data is recorded via an electronic case report
form (eCRF). Data will be monitored at all sites for com-
pleteness and quality by the contract research organization
(CRO). A full data-monitoring schedule will be established
and an independent data monitor will verify the eCRF
against the source data.
Any adverse events or serious adverse events are
recorded on the eCRF and forwarded to the sponsor and
the CRO immediately. An independent Data Monitoring
Committee will review serious adverse events and any
other trial safety issues.
Organisation
The trial has been approved by the ethics committees ei-
ther nationally or locally depending on site stipulations in
each country. A CRO has been contracted to oversee the
monitoring of all sites, establishing the eCRF and checking
the completeness and consistency of the trial data.
A trial steering group has been appointed to help the
chief investigator with the scientific aspects of the trial
and to oversee the progress of the trial. They will also




The sample size calculation is based on the primary end-
point of death, MI, and repeat revascularisation at one
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lence margin of 6% were assumed based on the results
of the FAME study [5]. A sample size of 826 would be
required to determine the non-inferiority of aCMR
guided strategy compared to an FFR guided strategy
with at least 80% power. Allowing for a dropout rate of
10% a total sample size of 918 patients is necessary. The
calculation was carried out using STATA 11SE.
We do anticipate that there will be crossover between
groups, most likely from the CMR group to the FFR
group, when patients continue to experience symptoms
and the CMR scan has been reported as negative. This
will be taken into consideration during the statistical
analysis which will be done on a per protocol and an
intention to treat basis.
Data analysis
Primary analysis
The main objective of this study is to assess whether an
“MR-INFORMED” management strategy is non-inferior
to an “FFR INFORMED” strategy for the clinical man-
agement of patients with angina who are at moderate to
high risk of CAD. To satisfy this objective the study will
test the following null-hypothesis:
H0: The difference in MACE incidence rates between
MRI and FFR group is above or equal to δ .
The outcome will be primarily assessed on an
intention to treat basis (mITT) and secondarily on a per
protocol (PP) analysis. The null hypothesis H0 can be
rejected and non-inferiority of the MR-guided strategy
claimed, if the two-sided 95% confidence interval (CI)
for the difference in incidence rates is completely below
δ in both the (mITT) and (PP) analysis. A difference of
6%-points was regarded as clinically relevant. Therefore
the non-inferiority margin was set to 6%-points.
In addition, absolute and relative frequencies will be
given per group. All statistical analyses will be carried
out by an independent statistician. A formal interim ana-
lysis is not planned in this study.
For all secondary efficacy variables, descriptive statis-
tics (n, mean, standard deviation, median, minimum,
and maximum) will be calculated for each quantitative
variable. Absolute and relative frequencies will be given
for categorical data.
Cost-utility analysis
The economic analysis will compare the total costs and
effectiveness within each arm of the treatment and pro-
vide incremental cost effectiveness ratio (ICER). It will
be computed as incremental costs divided by increment
quality adjusted life years (QALY). The total costs will
include both the direct and indirect costs. Costs will becomputed by recording patient utilisation of all NHS
services for the follow-up period of one year. These in-
clude, for instance, the costs of the initial diagnostic
procedures (CMR, coronary angiography and FFR),
revascularisation (PCI or CABG), hospitalisation costs,
pharmacy costs, optimal medical therapy costs over
the two years plus costs associated with any re-
hospitalisation due cardiac events (MI, repeat revasculari-
sation). These costs will be assessed using the NHS refer-
ence costs. Additional costs will be computed using
patient diaries and will include direct health care expendi-
tures plus total time off work (to compute lost income),
travel time and any travel or work time costs incurred by
home care givers (e.g. spouse, parent, etc.). Quality of Life
assessment will be carried out using the EQ5D question-
naire and will be administered at base line and every
two months for up to 24 months. Bootstrap methods
will be used to derive confidence intervals around the
ICER and to derive the Cost Effectiveness Acceptability
Curve (CEAC).
Study limitations
In this prospective outcome trial we address an import-
ant clinical question. There is currently insufficient evi-
dence on the comparative effectiveness of different
diagnostic strategies in patients with stable coronary ar-
tery disease and therefore we believe that the results of
this trial will help to inform future guidelines.
In order to achieve this objective, the trial has been
designed to reflect “real-world“ medical practice as
closely as possible. This is important for the translation
of its results into routine clinical practice. However, in-
evitably this leads to some limitations in the study
design.
Although we aim at optimising medical therapy in
both groups, there are variations on what is deemed op-
timal in different health systems and the implementation
of this is left to the primary care physician. We follow
the UK guidelines to minimise variation as much as pos-
sible, the remaining variation reflects clinical practice.
A critical point is the inclusion of peri-procedural
myocardial infarction and target lesion revascularisation
in our end-point. These endpoints are frequently used in
interventional trials. The occurrence of peri-procedural
myocardial infarctions seems an important end-point as
they are associated with adverse outcome and may re-
flect better guidance by one technique or the other.
However, as we guide revascularisation by objective
proof of ischaemia in both arms, we expect that all
patients in the trial are guided towards fewer revascular-
isation procedures compared to angiography alone and
that this will be reflected in low event rates in both
arms. The rationale for using target lesion revascularisa-
tion is similar.
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from one arm to another, which can be substantial (e.g.
COURAGE trial). We do not anticipate a high rate of
cross-over, however, the data monitoring committee will
assess the occurrence of cross-over and allow for adapta-
tion of the randomisation scheme to account for this.
Summary
MR–INFORM is an international, prospective, rando-
mised controlled, non-inferiority outcome trial compar-
ing the role of CMR perfusion to routine coronary
angiography with invasive fractional flow measurements
for guiding patients with stable angina and an inter-
mediate to high likelihood of coronary artery disease.
Non-inferiority of CMR perfusion imaging to the current
invasive reference standard (FFR) would establish CMR
perfusion imaging as an attractive, non-invasive alternative
to current diagnostic pathways. The results will help to in-
form national and international guidelines on the investi-
gation and management of coronary artery disease, and
ultimately lead to improved patient care.
Trial status
MR-INFORM is currently recruiting in the UK, Germany
and Portugal. There are currently six sites active in the
UK and one in Portugal and Germany. Another six
German sites and three UK sites are currently undergo-
ing ethics approval or contract negotiation and should
be initiated soon. The number of patients recruited at
the time of submission is 235.
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